PMID- 34873975
OWN - NLM
STAT- MEDLINE
DCOM- 20211221
LR  - 20220429
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 24
IP  - sup1
DP  - 2021 Nov
TI  - Trilaciclib and the economic value of multilineage myeloprotection from 
      chemotherapy-induced myelosuppression among patients with extensive-stage small 
      cell lung cancer treated with first-line chemotherapy.
PG  - 71-83
LID - 10.1080/13696998.2021.2014163 [doi]
AB  - AIMS: Proliferating hematopoietic stem and progenitor cells (HSPCs) are 
      susceptible to chemotherapy-induced damage, resulting in myelosuppressive adverse 
      events (AEs) such as neutropenia, anemia, and thrombocytopenia that are 
      associated with high health care costs and decreased quality of life (QoL). In 
      this study, a trial-based cost-effectiveness analysis was performed to help 
      assess the economic impact of administering trilaciclib, a myeloprotective 
      therapy that protects multilineage HSPCs from chemotherapy-induced damage, prior 
      to standard first-line chemotherapy, using data from a pivotal Phase II study of 
      trilaciclib in the setting of extensive-stage small cell lung cancer (ES-SCLC, 
      NCT03041311). METHOD: The aim of this study was to assess the cost-effectiveness 
      of administering trilaciclib prior to chemotherapy versus chemotherapy alone 
      among patients with ES-SCLC from a United States payer perspective. Data on the 
      rate and frequency of myelosuppressive AEs and health utility were derived from 
      the pivotal study of trilaciclib. Costs of managing myelosuppressive AEs and 
      costs of chemotherapy treatment were sourced from published literature. Outcomes 
      included the number of myelosuppressive AEs, costs (in 2021 US dollars), 
      quality-adjusted life-years (QALYs), incremental cost, incremental QALY, and an 
      incremental cost-effectiveness ratio. RESULTS: Administering trilaciclib prior to 
      chemotherapy was associated with a reduction in neutropenia (82%), febrile 
      neutropenia (75%), anemia (43%), and thrombocytopenia (96%) compared with 
      chemotherapy alone. Additionally, trilaciclib prior to chemotherapy was 
      cost-saving compared with chemotherapy alone ($99,919 vs $118,759, respectively) 
      and associated with QALY improvement (0.150 vs 0.145, respectively). 
      Probabilistic sensitivity analyses showed 58% of iterations projecting cost 
      savings and QALY improvement with trilaciclib. CONCLUSIONS: The findings suggest 
      that the use of trilaciclib prior to first-line chemotherapy in patients with 
      ES-SCLC can be cost-beneficial owing to fewer myelosuppressive AEs and lower 
      costs, together with a favorable QoL profile.
FAU - Abraham, Ivo
AU  - Abraham I
AUID- ORCID: 0000-0003-0490-4421
AD  - Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, 
      Tucson, AZ, USA.
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, University of 
      Arizona, Tucson, AZ, USA.
AD  - University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
AD  - Matrix45, Tucson, AZ, USA.
FAU - Onyekwere, Uchenna
AU  - Onyekwere U
AD  - ZS Associates, Evanston, IL, USA.
FAU - Deniz, Baris
AU  - Deniz B
AD  - ZS Associates, Evanston, IL, USA.
FAU - Moran, Donald
AU  - Moran D
AUID- ORCID: 0000-0001-7638-0618
AD  - G1 Therapeutics, Inc., Research Triangle Park, NC, USA.
FAU - Chioda, Marc
AU  - Chioda M
AD  - G1 Therapeutics, Inc., Research Triangle Park, NC, USA.
FAU - MacDonald, Karen
AU  - MacDonald K
AUID- ORCID: 0000-0002-4568-9783
AD  - Matrix45, Tucson, AZ, USA.
FAU - Huang, Huan
AU  - Huang H
AD  - G1 Therapeutics, Inc., Research Triangle Park, NC, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03041311
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - U6072DO9XG (trilaciclib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Pyrimidines
MH  - Pyrroles
MH  - Quality of Life
MH  - *Small Cell Lung Carcinoma
OTO - NOTNLM
OT  - Anemia
OT  - I
OT  - I00
OT  - I1
OT  - I10
OT  - chemotherapy-induced myelosuppression
OT  - economic evaluation
OT  - neutropenia
OT  - quality of life
OT  - thrombocytopenia
OT  - trilaciclib
EDAT- 2021/12/08 06:00
MHDA- 2021/12/22 06:00
CRDT- 2021/12/07 08:50
PHST- 2021/12/08 06:00 [pubmed]
PHST- 2021/12/22 06:00 [medline]
PHST- 2021/12/07 08:50 [entrez]
AID - 10.1080/13696998.2021.2014163 [doi]
PST - ppublish
SO  - J Med Econ. 2021 Nov;24(sup1):71-83. doi: 10.1080/13696998.2021.2014163.